In situ forming microparticle system for controlled delivery of leuprolide acetate: Influence of the formulation and processing parameters

被引:54
作者
Luan, XS [1 ]
Bodmeier, R [1 ]
机构
[1] Free Univ Berlin, Coll Pharm, D-12169 Berlin, Germany
关键词
in situ forming microparticle systems (ISM-systems); leuprolide acetate; initial release; polymer concentration; drug loading;
D O I
10.1016/j.ejps.2005.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of present study was to control the delivery of leuprolide acetate using in situ forming microparticle (ISM) systems. A solution of leuprolide acetate and poly(lactide-coglycolide) (PLGA RG 503H) or poly(lactide) (PLA R 202H) in N-methyl-2-pyrrolideone (NMP) was emulsified into an external oil phase using a two - syringe/connector system. After injection into an aqueous environment, NMP diffusion led to polymer precipitation and microparticle formation in situ. ISM-systems were characterized with respect to particle morphology and the influence of formulation and processing parameters on the in vitro release. ISM from RG 503H showed a high initial release (approximately 40%), which could be attributed to the high porosity of microparticles. The initial release could be reduced by increasing the polymer concentration, increasing the amount and viscosity of the oil phase, and decreasing the drug loading. ISM-systems from R 202H had a much lower initial release (approximately 9%) compared to that from RG 503H, which was followed by a slow and continuous drug release. In comparison to conventional microparticles prepared by a solvent evaporation method, ISM from R 202H showed a lower initial release and a more linear continuous release. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 22 条
[1]  
BODMEIER R, 1997, Patent No. 19724784
[2]   CONTROLLED DELIVERY SYSTEMS FOR PROTEINS BASED ON POLY(LACTIC GLYCOLIC ACID) MICROSPHERES [J].
COHEN, S ;
YOSHIOKA, T ;
LUCARELLI, M ;
HWANG, LH ;
LANGER, R .
PHARMACEUTICAL RESEARCH, 1991, 8 (06) :713-720
[3]  
Dunn R.L., 1990, U.S. Patent, Patent No. [4,938,763, 4938763, US patent no. 4,938,763]
[4]  
Gopferich A, 1996, EUR J PHARM BIOPHARM, V42, P1
[5]   Phase inversion dynamics of PLGA solutions related to drug delivery [J].
Graham, PD ;
Brodbeck, KJ ;
McHugh, AJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 58 (02) :233-245
[6]   Biodegradable injectable in situ forming drug delivery systems [J].
Hatefi, A ;
Amsden, B .
JOURNAL OF CONTROLLED RELEASE, 2002, 80 (1-3) :9-28
[7]   THE EFFECT OF PARTICLE MICROSTRUCTURE ON THE SOMATOSTATIN RELEASE FROM POLY(LACTIDE) MICROSPHERES PREPARED BY A W/O/W SOLVENT EVAPORATION METHOD [J].
HERRMANN, J ;
BODMEIER, R .
JOURNAL OF CONTROLLED RELEASE, 1995, 36 (1-2) :63-71
[8]   Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems [J].
Kranz, H ;
Brazeau, GA ;
Napaporn, J ;
Martin, RL ;
Millard, W ;
Bodmeier, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 212 (01) :11-18
[9]   DEVELOPMENT OF AN IN-SITU FORMING BIODEGRADABLE POLY-LACTIDE-CO-GLYCOLIDE SYSTEM FOR THE CONTROLLED-RELEASE OF PROTEINS [J].
LAMBERT, WJ ;
PECK, KD .
JOURNAL OF CONTROLLED RELEASE, 1995, 33 (01) :189-195
[10]   New lipid nanocapsules exhibit sustained release properties for amiodarone [J].
Lamprecht, A ;
Bouligand, Y ;
Benoit, JP .
JOURNAL OF CONTROLLED RELEASE, 2002, 84 (1-2) :59-68